Chair of Geriatric Medicine, University Duisburg-Essen, Essen, Germany.
Centre for Neuroscience & Stereology, Department of Neurology, Bispebjerg-Frederiksberg Hospital, University Hospital of Copenhagen, 2400, Copenhagen, Denmark.
Neurotherapeutics. 2022 Sep;19(5):1489-1502. doi: 10.1007/s13311-022-01288-7. Epub 2022 Sep 9.
The therapeutic strategies currently available for neurodegenerative diseases such as Parkinson's disease target only the symptoms of the disease. Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy can be summarized as synucleinopathies, as they are all characterized by the aggregation and accumulation of alpha-synuclein (α-syn) in the brain. Targeting α-syn by its formation and progression opens a new and promising disease-modifying therapeutic strategy. Thus, several distinct immunotherapeutic approaches are currently being evaluated in clinical trials. The objective of this article is to review, from a biological perspective, the most important properties of these passive and active immunotherapies to point out their relevance and suitability for the treatment of synucleinopathies.
目前用于治疗神经退行性疾病（如帕金森病）的策略仅针对疾病的症状。帕金森病、路易体痴呆和多系统萎缩可被总结为突触核蛋白病，因为它们的特征均为脑内α-突触核蛋白（α-syn）的聚集和积累。通过靶向 α-syn 的形成和进展，为疾病修饰治疗策略提供了新的、有前景的方法。因此，目前正在临床试验中评估几种不同的免疫疗法。本文的目的是从生物学角度回顾这些被动和主动免疫疗法的最重要特性，指出它们在治疗突触核蛋白病中的相关性和适用性。
